Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

NasdaqGM:ALT 1 Year Share Price vs Fair Value Explore Altimmune's Fair Values from the Community and select ...

NEW YORK - August 15, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.

Altimmune, Inc. ( NASDAQ: ALT) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K. Garg - President, CEO & ...

Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ...

Altimmune (NASDAQ:ALT) shares rose on Tuesday after the company reported promising Q2 results banking on its experimental candidate, pemvidutide. Pemvidutide is in development for the treatment of ...

UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial ...

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

Altimmune Inc. (NASDAQ: ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss.

Altimmune, a clinical-stage biopharmaceutical company, is making strides in its peptide research, developing therapeutic agents with the potential to treat serious health conditions like liver ...